Douglas van Marel, MD
Hospitalist · Huron, SDNPI 1427144179
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 26.3% of the total. Among hospitalist clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Amgen$857
- Boehringer Ingelheim$763
- GSK$608
- Lilly USA, LLC$583
- plus $1K from 17 others
What the payments were for
- Food & beverage$7,017100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 86 | $1,856 |
| AstraZeneca | 21 | $1,010 |
| Amgen | 37 | $857 |
| Boehringer Ingelheim | 23 | $763 |
| GSK | 44 | $608 |
| Lilly USA, LLC | 14 | $583 |
| Bayer | 4 | $251 |
| Otsuka America Pharmaceutical, Inc. | 9 | $214 |
| AbbVie(2 entities) | 7 | $190 |
| Novartis | 18 | $168 |
| Johnson & Johnson | 3 | $110 |
| Astellas Pharma US Inc | 4 | $78 |
| Pfizer | 5 | $66 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Avanir Pharmaceuticals, Inc. | 3 | $42 |
| Merck | 3 | $37 |
| Dexcom, Inc. | 2 | $37 |
| KCI USA, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $20 |
| Alkermes, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,043 in reported general payments places this provider in the 95th percentile of 81 hospitalist providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 233 | $260,963 |
| OzempicSemaglutide | 171 | $238,591 |
| FarxigaDapagliflozin Propanediol | 202 | $213,021 |
| EliquisApixaban | 132 | $153,312 |
| TrulicityDulaglutide | 99 | $123,346 |
| MounjaroTirzepatide | 75 | $112,992 |
| JanuviaSitagliptin Phosphate | 85 | $95,387 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $85,936 |
| RybelsusSemaglutide | 33 | $50,524 |
| XareltoRivaroxaban | 47 | $48,513 |
| EntrestoSacubitril/Valsartan | 36 | $39,216 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $38,072 |
| TradjentaLinagliptin | 38 | $31,208 |
| Repatha SureclickEvolocumab | 28 | $28,249 |
| KerendiaFinerenone | 12 | $21,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $763 | $308,905288 claims |
| Novo NordiskOzempic, Rybelsus | $1,856 | $289,115204 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $583 | $236,338174 claims |
| AstraZenecaFarxiga | $1,010 | $213,021202 claims |
| PfizerEliquis, Nurtec Odt | $66 | $173,249144 claims |
| MerckJanuvia | $37 | $95,38785 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $608 | $95,31185 claims |
| Johnson & JohnsonXarelto | $110 | $48,51347 claims |
| NovartisEntresto | $168 | $39,21636 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $42 | $38,07217 claims |
| BayerKerendia | $251 | $21,21812 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $16,78218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 hospitalist providers in South Dakota.
Other hospitalist in Huron
- Kristen HughesHuron$185
- Emmanuel FohleSioux Falls$9K
- Andreea-Constanta StanSioux Falls$1K
- Swetha AlapatiSioux Falls$747
- John LoobyRapid City$365
- Jeremy CauwelsSioux Falls$359
- Melanie LavoieSioux Falls$309
- Julian RoblesSioux Falls$293
- Shaheen FaruqueRosebud$291
- Ellis EasterlingSioux Falls$220
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.